Carl Dambkowski, Director at Oruka Therapeutics, Inc. (ORKA), sold 35,000 shares at $70.13 ($2.5M) on 2026-06-11, disclosed to the SEC on 2026-06-12.
Scheduled sale ($2.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $70.13 | 22,417 | $1.6M | 64.1% |
| 2 | $70.11 | 12,583 | $882K | 35.9% |
| Total | $70.13 avg | 35,000 | $2.5M | 100% |
| Filing → |
| APGE | SELL | 2026-06-05 | $433K | — | Filing → |
| ORKA | SELL | 2026-05-22 | $6.2M | — | Filing → |
| APGE | SELL | 2026-05-08 | $463K | — | Filing → |